MKD / Molecular Data Inc - ADR - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

US60852L2051 / MOLECULAR DATA INC SPON ADR / TB Alternative Assets Ltd. - SC 13G Passive Investment

SC 13G 1 d740370dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L205** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Che

MKD / Molecular Data Inc - ADR / Streeterville Capital LLC - NONE Passive Investment

SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106 (CUSIP Number) Calendar Year 2023 (Date of Event Which Requires Filing of this Statement) Chec

US60852L2051 / MOLECULAR DATA INC SPON ADR / TB Alternative Assets Ltd. - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L205** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

MKD / Molecular Data Inc. / TB Alternative Assets Ltd. - SCHEDULE 13G Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

MKD / Molecular Data Inc. / Streeterville Capital LLC - NONE Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167 Molecular Data, Inc. (Translation of registrant?s name into English) 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s

Molecular Data Receives De-Listing Notice from NASDAQ

Exhibit 99.1 Molecular Data Receives De-Listing Notice from NASDAQ Shanghai, China, May 27, 2022 ? Molecular Data, Inc. (?Molecular Data? or the ?Company?) (NASDAQ: MKD), a technology-driven platform in China, announced today that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC (?Nasdaq?), notifying the Company that its minimum closing bid price per share for its ordinar

Molecular Data Inc. Announces ADS Ratio Change

Exhibit 99.1 Molecular Data Inc. Announces ADS Ratio Change Shanghai, China (May 20, 2022) ? Molecular Data Inc. (NASDAQ: MKD) (the ?Company?) announced today a ratio change on its American Depositary Shares (?ADS?) from the current one (1) ADS representing three (3) Class A ordinary shares to the new ratio of one (1) ADS representing forty-five (45) Class A ordinary shares (the ?Ratio Change?). T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executive

Molecular Data Inc. Announces Receipt of Nasdaq Non-Compliance Letter

Exhibit 99.1 Molecular Data Inc. Announces Receipt of Nasdaq Non-Compliance Letter Shanghai, China (May 20, 2022) ? Molecular Data Inc. (NASDAQ: MKD) (the ?Company?) announced today that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the ?Letter?) from The Nasdaq Stock Market LLC (?Nasdaq?) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executive

Deposit Agreement, dated as of December 27, 2019, among Molecular Data Inc. (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all Holders and Beneficial Owners from time to time of American Depositary Receipts ("ADRs") issued thereunder.

Exhibit (a)(1) Execution Version TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1.

Form of Amendment No. 1 to Deposit Agreement among the Company, the Depositary and all Holders and Beneficial Owners from time to time of ADRs issued thereunder, including the form of ADR attached as Exhibit A thereto.

Exhibit (a)(2) AMENDMENT NO. 1, dated as of , 2022 (the "Amendment"), to the Deposit Agreement dated as of December 27, 2019 (as amended from time to time, the "Deposit Agreement") among Molecular Data Inc. and its successors (the ?Company?), JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all Holders and Beneficial Owners from time to time of American depositary receipts ("ADRs")

As filed with the U.S. Securities and Exchange Commission on May 13, 2022

As filed with the U.S. Securities and Exchange Commission on May 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MOLECULAR DATA INC. (Exact name of issuer of deposited securities as specified in its charter) N/A (Tra

Opinion of Norton Rose Fulbright US LLP, counsel to the Depositary, as to the legality of the securities being registered.

Exhibit (d) May 13, 2022 Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, New York 10019-6022 United States JPMorgan Chase Bank, N.

Rule 466 Certification.

Exhibit (e) Rule 466 Certification The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: i. That it previously had filed a registration statement on Form F-6 (File No. 333-235619), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement; and ii. That its abilit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: DECEMBER 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

MKD / Molecular Data Inc. / SHEN NEIL NANPENG - SC 13G/A Passive Investment

SC 13G/A 1 d253872dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* MOLECULAR DATA INC. (Name of Issuer) Class A Ordinary Shares, par value $0

MKD / Molecular Data Inc. / TB Alternative Assets Ltd. - SCHEDULE 13G Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

MKD / Molecular Data Inc. / TB Alternative Assets Ltd. - SCHEDULE 13G Passive Investment

SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

MKD / Molecular Data Inc. / Hudson Bay Capital Management LP - MKD 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Molecular Data Inc. (Name of Issuer) Class A Ordinary shares, par value $0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China (Address of principal exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China (Address of principal exec

Placement Agency Agreement, dated September 15, 2021, between the Company and Aegis Capital Corp.

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT September 15, 2021 PERSONAL AND CONFIDENTIAL Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai, People?s Republic of China 201106 Attention: Steven Foo Chief Executive Officer Dear Mr. Foo: Introduction. Subject to the terms and conditions herein (this ?Agreement?), Molecular Data Inc. (the ?Company?), hereby agrees to sell u

Form of Warrant

Exhibit 4.2 PURCHASE WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES MOLECULAR DATA INC. Warrant ADSs.: [ ] Issue Date: September 17, 2021 Initial Exercise Date: September 17, 2021 THIS WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entit

Form of Securities Purchase Agreement, dated September 15, 2021, between the Company and the Purchasers

Exhibit 1.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 15, 2021, between Molecular Data Inc., a company incorporated under the laws of the Cayman Islands (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal exe

Molecular Data Inc. Prices $15 Million Registered Direct Offering

Exhibit 99.1 Molecular Data Inc. Prices $15 Million Registered Direct Offering SHANGHAI, Sept. 15, 2021 /PRNewswire/ - Molecular Data Inc. (Nasdaq: MKD), a leading technology-driven platform in China?s chemical industry, today announced it has entered into definitive agreements with investors for the purchase and sale pursuant to a registered direct offering of (i) common units, consisting of one

23,390,000 Common Units 16,083,684 Pre-funded Units Molecular Data Inc. Each Common Unit Consisting of One American Depositary Share and One Warrant to Purchase One American Depositary Share Each Pre-funded Unit Consisting of One Pre-funded Warrant a

Filed pursuant to Rule 424(b)(5) Registration No. 333-256451 Prospectus Supplement (To Prospectus dated June 23, 2021) 23,390,000 Common Units 16,083,684 Pre-funded Units Molecular Data Inc. Each Common Unit Consisting of One American Depositary Share and One Warrant to Purchase One American Depositary Share Each Pre-funded Unit Consisting of One Pre-funded Warrant and One Warrant to Purchase One

Form of Pre-Funded Warrant

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES MOLECULAR DATA INC. Warrant No.: Issue Date: September 16, 2021 Initial Exercise Date: September 16, 2021 Number of American Depositary Shares: [ ] THIS PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the ?Warrant?) certifies that, for value

6,000,000 American Depositary Shares Representing 18,000,000 Class A Ordinary Shares Molecular Data Inc.

424B5 1 moleculardata424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-256451 Prospectus Supplement (To Prospectus dated June 23, 2021) 6,000,000 American Depositary Shares Representing 18,000,000 Class A Ordinary Shares Molecular Data Inc. Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 6,000,000 American Depositary Shares, or ADSs, each

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal exe

PROSPECTUS SUPPLEMENT

Filed Pursuant to Rule 424(b)(7) Registration No. 333-256451 PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) 10,550,000 American Depositary Shares Representing 31,650,000 Class A Ordinary Shares and 21,000,000 Class A Ordinary Shares Molecular Data Inc. This prospectus relates to the offer and sale from time to time of up to an aggregate of up to 10,000,000 American Depositary Shares, or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001- 3916

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China (Address of principal executiv

$2,000,000 Convertible Debenture Convertible into American Depositary Shares Molecular Data Inc.

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(5)  Registration No. 333-256451 Prospectus Supplement (To Prospectus dated June 23, 2021) $2,000,000 Convertible Debenture Convertible into American Depositary Shares Molecular Data Inc. Pursuant to this prospectus supplement and the accompanying prospectus, we are offering $2,000,000 in the principal amount of our convertible debenture (the “Conver

SECURITIES PURCHASE AGREEMENT

Exhibit 99.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of July 14, 2021, is between MOLECULAR DATA INC., a company incorporated under the laws of the Cayman Islands, with principal executive offices located at 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District, Shanghai 201109, Peoples Republic of China (the ?Company?), the investors liste

PROSPECTUS SUPPLEMENT

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-256451? PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2021) MOLECULAR DATA INC. Up to 20,000,000 American Depositary Shares Representing 60,000,000 Class A Ordinary Shares 1,141,667 Class A Ordinary Shares This prospectus relates to the offer and sale from time to time of up to an aggregate of up to 20,000,000 America

amended on June 21, 2021

20-F/A 1 a21-20022120fa.htm 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR o TRANSITION REPO

Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China June 21, 2021

Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China June 21, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Molecular Data Inc. Registration Statement on Form F-3, as amended Originally filed on May 25, 2021 Registration No. 333-256451 De

As filed with the Securities and Exchange Commission on June 11, 2021

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 11, 2021 REGISTRATION NO.

Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China June 11, 2021

Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China June 11, 2021 Jennifer L?pez Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-4631 Re: Molecular Data Inc. Registration Statement on Form F-3 Filed May 25, 2021 File No. 333-256451 Dear Ms. L?pez: On behalf of Molecul

Form of indenture with respect to debt securities, to be entered into between registrant and a trustee acceptable to the registrant, if any

Exhibit 4.14 Molecular Data Inc. INDENTURE Dated as of [ ] [ ] TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions. 1 Section 1.2 Other Definitions. 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 4 Section 1.4 Rules of Construction. 4 ARTICLE II TERMS OF THE SECURITIES 4 Section 2.1 Issuable in Series. 4 Section 2.2 Establishment of Te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167

6-K 1 a21-1762616k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of China (Add

Form of Equity Purchase Agreement between the Registrant and Oasis Capital, LLC, including a

Exhibit 4.9 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this "Agreement") is entered into as of 13 May, 2021 (the "Execution Date"), by and between Molecular Data Inc., a company incorporated under the laws of the Cayman Islands (the "Company"), and Oasis Capital, LLC, a Puerto Rico limited liability company (the "Investor"). RECITALS WHEREAS, the parties desire that, upon the terms

Form F-3 (File No. 333-256451) that we filed with the SEC on June 7, 2021

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 24, 2021 REGISTRATION NO.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executive

EQUITY PURCHASE AGREEMENT

Exhibit 99.1 Molecular Data announces that it entered into an agreement with Oasis Capital, LLC to sell up to $50 million of ADRs to Oasis from time to time. EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this "Agreement") is entered into as of 13 May, 2021 (the "Execution Date"), by and between Molecular Data Inc., a company incorporated under the laws of the Cayman Islands (the "Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167

6-K 1 tm2116648d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People’s Republic of Chin

CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 ? Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 ? In connection with the Annual Report of Molecular Data Inc. (the ?Company?) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Steven Foo, Chief Executive Officer of the Company, certify

CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Molecular Data Inc. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Foo, Chief Financial Officer of the Company, certify, pu

Letter from Ernst & Young Hua Ming LLP dated May 17, 2021

Exhibit 16.1 ? May 17, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and gentlemen: We have read item 16F of Form 20-F dated May 17, 2021, of Molecular Data Inc. and are in agreement with the statements contained in the second and third sentences of paragraph one, paragraph three and four of Change in our Certifying Accountant on page 128 therein. We have n

CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 ? Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? I, Steven Foo, certify that: ? 1. I have reviewed this annual report on Form 20-F of Molecular Data Inc.; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i

Consent Letter of Shandong Haoxin Certified Public Accountants Co., Ltd. dated May 17, 2021

Exhibit 15.1 CONSENT OF Shandong Haoxin Certified Public Accountants Co., Ltd. We hereby consent to the incorporation by reference in this Annual Report on Form 20-F of Molecular Data Inc. of our report dated May 12, 2021 relating to the financial statements, which appears in this Form 20-F. /s /s/ Shandong Haoxin Certified Public Accountants Co., Ltd. Weifang, the People’s Republic of China May 1

Form 20-F

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Steven Foo, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Data Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executive

Molecular Data announces that it entered into an agreement with Oasis Capital, LLC to sell up to $50 million of ADRs to Oasis from time to time.

Exhibit 99.1 Molecular Data announces that it entered into an agreement with Oasis Capital, LLC to sell up to $50 million of ADRs to Oasis from time to time.

- NT 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K x Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2020 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition Pe

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. __________

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title o

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106 (CUSIP Number) April 09, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropri

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of April 7, 2021, by and among MOLECULAR DATA INC., a company formed and existing under the laws of the Cayman Islands (the ?Company?), and Streeterville Capital, LLC, a Utah limited liability company (the ?Investor?). WHEREAS: A. In connection with the Securities Purchase Agreement by and am

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executi

SECURITIES PURCHASE AGREEMENT

Exhibit 99.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 7, 2021, is between MOLECULAR DATA INC., a company incorporated under the laws of the Cayman Islands, with principal executive offices located at11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106, Peoples Republic of China (the ?Company?), and each of the investor

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executi

Molecular Data has raised up to USD 7.5 million from an accredited investor

Exhibit 99.1 Molecular Data has raised up to USD 7.5 million from an accredited investor

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001- 39167 Molecular Data Inc. 11/F, Building 15, 2177 Shenkun Road Minhang District, Shanghai 201106 People?s Republic of China (Address of principal executi

CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of RMB and US$, except for number of shares and per share data)

Exhibit 99.1 Molecular Data announces additional disclosures for half year 2020 results CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of RMB and US$, except for number of shares and per share data) For the years ended December 31, As of June 30, 2020 2019 2020 (RMB’000) (RMB’000) unaudited (USD’000) CASH FLOWS FROM OPERATING ACTIVITIES Net loss (193,548 ) (104,936 ) (14,853 ) Adjustm

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People?s Republic of China (Address of principal exec

ORDINARY SHARE PURCHASE AGREEMENT

Exhibit 99.2 ORDINARY SHARE PURCHASE AGREEMENT This Ordinary Share Purchase Agreement is entered into effective as of this 3rd day of March, 2021 (this “Agreement”), by and between MOLECULAR DATA INC., a Cayman Islands corporation (the “Company”), and WHITE LION CAPITAL LLC, a Nevada limited liability company (the “Investor”). WHEREAS, the parties desire that, upon the terms and subject to the con

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 3, 2021 (the “Execution Date”), is entered into by and between Molecular Data Inc., a Cayman Islands corporation (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not o

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People?s Republic of China (Address of principal exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Cl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exc

SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No.1)* MOLECULAR DATA INC. (Name of Issuer) Class A Ordinary Shares, par value $0.00005 per share (Title of Clas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Cl

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) 12/06/2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Cl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) June 30, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig

Joint Filing Agreement, dated February 5, 2021, by and among TR Grand Fund Inc., TR Dingsheng (Wuhan) Investment Center (Limited Partner) and Tianfeng Huiying (Wuhan) Investment Management Co., Ltd.

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) December 31, 2020 and January 6, 2021*** (Date of Event which Requires Filing of this Statement) Check

Molecular Data Inc. Announces First Half 2020 Management Financial Results

Exhibit 99.1 Molecular Data Inc. Announces First Half 2020 Management Financial Results SHANGHAI, December 31, 2020 – Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced its management financial results for the six months ended June 30, 2020. First Half 2020 Financial Highlights · Net revenues in

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (Address of principal e

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (Address of principal e

Molecular Data Inc. Announces Changes of Chief Financial Officer

Exhibit 99.1 Molecular Data Inc. Announces Changes of Chief Financial Officer SHANGHAI, China, December 2, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has te

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (Address of principal e

Current Report of Foreign Issuer - 6-K

6-K 1 a20-3415216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of Chi

Molecular Data Inc. Announces Change of Independent Registered Public Accounting Firm

Exhibit 99.1 Molecular Data Inc. Announces Change of Independent Registered Public Accounting Firm SHANGHAI, China, October 23, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that, effective October 23, 2020, the Company has appointed Marcum Bernstein & Pinchuk LLP (“MarcumBP”) as the

REGISTRATION RIGHTS AGREEMENT

Exhibit 99.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 9 , 2020, by and among MOLECULAR DATA INC., a company formed and existing under the laws of the Cayman Islands (the “Company”), and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Investor”). WHEREAS: A. In connection with the Securities Purchase Agreement by and

Molecular Data Inc. Announces Private Placement of up to US$5.0 Million Convertible Debentures

Exhibit 99.1 Molecular Data Inc. Announces Private Placement of up to US$5.0 Million Convertible Debentures SHANGHAI, China, October 13, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (NASDAQ: MKD), a leading technology-driven platform in China’s chemical industry, today announced that it has entered into definitive agreement with YA II PN, Ltd., a Cayman Islands exempt limited par

Current Report of Foreign Issuer - 6-K

6-K 1 a20-3307416k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of Chi

SECURITIES PURCHASE AGREEMENT

EX-99.2 3 a20-330741ex99d2.htm EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 9 , 2020, is between MOLECULAR DATA INC., a company incorporated under the laws of the Cayman Islands, with principal executive offices located at 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District, Shanghai 201109, Peoples Republic of

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (Address of principal

MKD / Molecular Data Inc. / Fosun International Ltd - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) June 30, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig

Joint Filing Agreement, dated July 10, 2020 by and between Greatest Investments Limited and Fosun International Limited.

Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including a

- S-8

As filed with the Securities and Exchange Commission on July 2, 2020 Registration No.

CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Zheng Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Data Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

Molecular Data Inc. Announces Share Distribution

EX-99.1 2 a20-129685ex99d1.htm EX-99.1 Exhibit 99.1 Molecular Data Inc. Announces Share Distribution SHANGHAI, China, June 30, 2020 (GLOBE NEWSWIRE) — Molecular Data Inc. (“Molecular Data” or the “Company”) (NASDAQ: MKD), a leading technology-driven platform in China’s chemical industry, today announced that it has completed the distribution of the Company’s ordinary shares held by MOLBASE Inc. (“

CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Molecular Data Inc. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zhaohong Li, Chief Financial Officer of the Company, certify, p

CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Zhaohong Li, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Data Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

Annual Report (Form 20-F) at December 31, 2019,

20-F 1 a20-12968120f.htm 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR o TRANSITION REPORT PURS

CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Molecular Data Inc. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zheng Wang, Chief Executive Officer of the Company, certify, pu

Consent of Global Law Office

Exhibit 15.1 [Global Law Office Letterhead] Date: June 30, 2020 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China Dear Sir/Madam: We hereby consent to the use of our name and the summary of our opinion under the headings, “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure”, “Item 4. Information on

Description of securities

EX-2.4 2 a20-129681ex2d4.htm EX-2.4 Exhibit 2.4 DESCRIPTION OF RIGHTS OF EACH CLASS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 (THE “EXCHANGE ACT”) Class A ordinary shares, par value US$0.00005 per share, of Molecular Data Inc. (“we,” “our,” “our company,” or “us”) are registered under Section 12(b) of the Exchange Act, and our American depositary shares (“ADS

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (Address of principal execu

- NT 20-F

SEC FILE NUMBER: 001-39167 CUSIP NUMBER: 60852L 106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Molecular Data Inc. Announces Appointment of Independent Director

Exhibit 99.1 Molecular Data Inc. Announces Appointment of Independent Director SHANGHAI, CHINA, May 20, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that Mr. Yanbin Wang has been appointed as a new independent director to the Company’s board of directors (the “Board”), effective May

Current Report of Foreign Issuer - 6-K

6-K 1 a20-2029616k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (

Molecular Data Inc. Announces the Establishment of its Strategy Advisory Committee

Exhibit 99.1 Molecular Data Inc. Announces the Establishment of its Strategy Advisory Committee SHANGHAI, China, May 8, 2020 (GLOBE NEWSWIRE) — Molecular Data Inc. (“Molecular Data” or the “Company”) (NASDAQ: MKD), a leading technology-driven platform in China’s chemical industry, today announced that it has formed a strategy advisory committee and has appointed Junling Li, former vice president o

Current Report of Foreign Issuer - 6-K

6-K 1 a20-1907216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China (

Current Report of Foreign Issuer - 6-K

6-K 1 a20-1806216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China

MKD / Molecular Data Inc. 6-K - Current Report of Foreign Issuer - 6-K

6-K 1 a20-1525816k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China

MKD / Molecular Data Inc. 6-K - Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China (Address of principal exec

MKD / Molecular Data Inc. 6-K - Current Report of Foreign Issuer - 6-K

6-K 1 a20-1401316k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China

MKD / Molecular Data Inc. 6-K - Current Report of Foreign Issuer - 6-K

6-K 1 a20-1386216k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China

Molecular Data Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results

Exhibit 99.1 Molecular Data Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results SHANGHAI, March 25, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2019. Fourth Quarter a

MKD / Molecular Data Inc. 6-K - Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2020 Commission File Number: 001- 39167 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road, Xuhui District Shanghai 201109 People’s Republic of China (Address of principal e

MKD / Molecular Data Inc. / SHEN NEIL NANPENG - SC 13G Passive Investment

SC 13G 1 d886240dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* MOLECULAR DATA INC. (Name of Issuer) Class A Ordinary Shares, par value $0.00005

JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) Molecular Data, Inc.

Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) Molecular Data, Inc. The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statem

MKD / Molecular Data Inc. / Xu Ping Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data, Inc. (Name of Issuer) Class A Ordinary Shares, par value US$0.00005 per share (Title of Class of Securities) 60852L106** (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Joint Filing Agreement

EX-99.1 2 a20-74591ex99d1.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments t

MKD / Molecular Data Inc. / CHANG Dongliang - SC 13G Passive Investment

SC 13G 1 a20-74591sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13D-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13D-1(B), (C) AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Molecular Data Inc. (Name of Issuer) Class A ordinary shares, par value of $0.0

11,500,000 American Depositary Shares Molecular Data Inc. Representing 34,500,000 Class A Ordinary Shares

424(b)(4) Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-235398 11,500,000 American Depositary Shares Molecular Data Inc. Representing 34,500,000 Class A Ordinary Shares This is an initial public offering of American depositary shares, or ADSs, of Molecular Data Inc. Each ADS represents three of our Class A ordinary shares, par value US$0.00005 per share. Prior to this off

MKD / Molecular Data Inc. CORRESP - -

December 23, 2019 VIA EDGAR Office of International Corporate Finance Division of Corporation Finance U.

MKD / Molecular Data Inc. CORRESP - -

December 23, 2019 VIA EDGAR Ms. Barbara Jacobs Mr. Michael C. Foland Mr. Stephen Krikorian Ms. Morgan Youngwood U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 U. S. A. Re: Molecular Data Inc. (CIK No. 0001758736) Registration Statement on Form F-1 (File No. 333-235398) Registration Statement on Form 8-A (File No. 001-39167) Dear Ladi

MKD / Molecular Data Inc. CORRESP - -

CORRESP 1 filename1.htm AMTD Global Markets Limited 23/F-25/F, Nexxus Building, 41 Connaught Road Central, Hong Kong Boustead Securities LLC 6 Venture, Suite 395, Irvine, CA 92618 United States of America Fosun Hani Securities Limited Suite 2101-2105, 21/F, Champion Tower 3 Garden Road, Central Hong Kong VIA EDGAR December 23, 2019 Ms. Barbara Jacobs Mr. Michael C. Foland Mr. Stephen Krikorian Ms.

DMLRY / Daimler AG F-6 - - REGISTRATION STATEMENT FOR AMERICAN DEPOSITARY RECEIPTS

As filed with the U.S. Securities and Exchange Commission on December 20, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Molecular Data Inc. (Exact name of issuer of deposited securities as specified in its charter) N/A

Opinion of Pepper Hamilton LLP, counsel to the Depositary, as to the legality of the securities to be registered.

JPMORGAN CHASE BANK, N.A. F-6 Exhibit (d) The New York Times Building 37th Floor 620 Eighth Avenue New York, NY 10018-1405 212.808.2700 Fax 212.286.9806 Exhibit (d) December 20, 2019 JPMorgan Chase Bank, N.A., as Depositary 383 Madison Avenue, Floor 11 New York, NY 10179 Re: Registration Statement on Form F-6 – American Depositary Shares evidenced by American Depositary Receipts for deposited Clas

As filed with the Securities and Exchange Commission on December 20, 2019

Table of Contents As filed with the Securities and Exchange Commission on December 20, 2019 Registration No.

Registrant’s Specimen Certificate for Class A Ordinary Shares (incorporated herein by reference to Exhibit 4.2 to the Form F-1/A filed on December 20, 2019 (File No. 333-235398))

Exhibit 4.2 MOLECULAR DATA INC. Number Class A Shares Incorporated under the laws of the Cayman Islands Share capital is US$50,000 divided into (i) 550,000,000 Class A Ordinary Shares of a par value of US$0.00005 each; (ii) 350,000,000 Class B Ordinary Shares of a par value of US$0.00005 each; and (iii) 100,000,000 Shares of a par value of US$0.00005 each THIS IS TO CERTIFY THAT is the registered

Form of Underwriting Agreement

EX-1.1 2 d634677dex11.htm EX-1.1 Exhibit 1.1 34,500,000 Shares MOLECULAR DATA INC. CLASS A ORDINARY SHARES, PAR VALUE US$0.00005 PER SHARE IN THE FORM OF AMERICAN DEPOSITARY SHARES UNDERWRITING AGREEMENT [•], 2019 AMTD Global Markets Limited 23/F-25/F, Nexxus Building, 41 Connaught Road Central, Hong Kong Boustead Securities LLC 6 Venture, Suite 395, Irvine, CA 92618 United States of America Fosun

MKD / Molecular Data Inc. CORRESP - -

CORRESP 1 filename1.htm SKADDEN, ARPS, SLATE, MEAGHER & FLOM DIRECT DIAL +852 3740 4863 DIRECT FAX +852 3910 4863 EMAIL ADDRESS [email protected] PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ JONATHAN B. STONE * PALOMA P. WANG ◆ (ALSO ADMITTED IN ENGLAND & WALES) * (ALSO ADMITTED IN NEW YORK) REGISTERED FORE

Form of Deposit Agreement among Molecular Data Inc., JPMorgan Chase Bank, N.A., as depositary, and all holders and beneficial owners from time to time of ADRs issued thereunder, including the form of American Depositary Receipt attached as Exhibit A thereto.

JPMORGAN CHASE BANK, N.A. F-6 Exhibit (a) TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 1 (e) Custodian 2 (f) Deliver, execute, issue et al. 2 (g) Delivery Order 2 (h) Deposited Securities 2 (i) Direct Registration System 2 (j) Holder 2 (k) Securities Act of 1933 3 (l) Securities Exc

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Molecular Data Inc. (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificati

Consent of Frost & Sullivan

Exhibit 99.3 [Frost & Sullivan Letterhead] December 6, 2019 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 The People?s Republic of China +86 21-5436-5166 Re: Molecular Data Inc. Ladies and Gentlemen, We understand that Molecular Data Inc. (the ?Company?) plans to file a registration statement on Form F-1 (the ?Registration Statement?) with the United

English translation of exclusive option agreement dated December 21, 2018 among Shanghai MOHUA, Shanghai MOLBASE and the shareholders of Shanghai MOLBASE (incorporated herein by reference to Exhibit 10.6 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.6 11 d634677dex106.htm EX-10.6 Exhibit 10.6 English Translation Exclusive Option Agreement This Exclusive Option Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Obligee): Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterprise legally established

English translation of exclusive option agreement dated December 21, 2018 among Shanghai MOHUA, Jiaxing MOLBASE and the shareholders of Jiaxing MOLBASE (incorporated herein by reference to Exhibit 10.10 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.10 English Translation Exclusive Option Agreement This Exclusive Option Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Obligee): Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterprise legally established and validly existing under the laws

Form of Deposit Agreement among the Registrant, the depositary and holder of the American Depositary Receipts (incorporated herein by reference to Exhibit 4.3 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-4.3 4 d634677dex43.htm EX-4.3 Exhibit 4.3 TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Beneficial Owner 2 (e) Custodian 2 (f) Deliver, execute, issue et al. 2 (g) Delivery Order 2 (h) Deposited Securities 2 (i) Direct Registration System 2 (j) Holder 2 (k) Securities Act of 1933 3 (l) Securities

Form of Indemnification Agreement between the Registrant and its directors and executive officers (incorporated herein by reference to Exhibit 10.3 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.3 8 d634677dex103.htm EX-10.3 Exhibit 10.3 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of , 2019 by and between Molecular Data Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and (Passport/ID Card No. ) (the “Indemnitee”). WHEREAS, the Indemnitee has agreed to serve as a director or officer o

English translation of equity pledge agreement dated December 21, 2018 among Shanghai MOHUA, Shanghai MOLBASE and the shareholders of Shanghai MOLBASE (incorporated herein by reference to Exhibit 10.5 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.5 English Translation Equity Pledge Agreement This Equity Pledge Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Pledgee): Shanghai MOHUA Information Technology Co., Ltd., a wholly foreign owned enterprise legally established and validly existing under the laws of the

Powers of Attorney (included on signature page)

Table of Contents As filed with the Securities and Exchange Commission on December 6, 2019 Registration No.

Opinion of Global Law Office regarding certain PRC tax matters (included in Exhibit 99.2)

Exhibit 99.2 December 6, 2019 To: Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People?s Republic of China Dear Sirs or Madams: We are qualified lawyers of the People?s Republic of China (the ?PRC? or ?China?) and are qualified to issue opinions on the PRC Laws (the ?Opinion?). For the purpose of this Opinion, the PRC shall not include the Hong Kong

Memorandum and Articles of Association of the Registrant, as currently in effect

EX-3.1 2 d634677dex31.htm EX-3.1 Exhibit 3.1 THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. Maricorp Services Ltd. 31 The Strand PO Box 2075 Grand Cayman KY1-1105 Cayman Islands i THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. (the “C

English translation of shareholders’ voting rights proxy agreement dated December 21, 2018 among Shanghai MOHUA, Shanghai MOLBASE and the shareholders of Shanghai MOLBASE (incorporated herein by reference to Exhibit 10.7 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.7 English Translation Shareholders? Voting Rights Proxy Agreement This Shareholders? Voting Rights Proxy Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Shareholders): Dongliang Chang Identification No.: Zhengyu Wu Identification No.: Party B (the Company): Shanghai MO

English translation of shareholders’ voting rights proxy agreement dated December 21, 2018 among Shanghai MOHUA, Jiaxing MOLBASE and the shareholders of Jiaxing MOLBASE (incorporated herein by reference to Exhibit 10.11 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.11 16 d634677dex1011.htm EX-10.11 Exhibit 10.11 English Translation Shareholders’ Voting Rights Proxy Agreement This Shareholders’ Voting Rights Proxy Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Shareholders): Dongliang Chang Identification No.: Zhengyu Wu Identificatio

English translation of exclusive technical support and service agreement dated December 21, 2018 among Shanghai MOHUA and Shanghai MOLBASE (incorporated herein by reference to Exhibit 10.8 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.8 English Translation Exclusive Technical Support and Service Agreement This Exclusive Technical Support and Service Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A: Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterprise legally established a

Amended and Restated Memorandum and Articles of Association of the Registrant, effective January 2, 2020 (incorporated herein by reference to Exhibit 3.2 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-3.2 3 d634677dex32.htm EX-3.2 Exhibit 3.2 THE COMPANIES LAW (2018 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. (adopted by a Special Resolution passed on October 8, 2019 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing its Cl

2019 Share Incentive Plan (incorporated herein by reference to Exhibit 10.2 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.2 7 d634677dex102.htm EX-10.2 Exhibit 10.2 MOLECULAR DATA INC. 2019 SHARE INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the Plan is to promote the success and enhance the value of Molecular Data Inc., an exempted company formed under the laws of the Cayman Islands (the “Company”), by linking the personal interests of the Directors, Employees, and Consultants to those of the Company’s share

Principal Subsidiaries and VIEs of the Registrant

Exhibit 21.1 Principal Subsidiaries and Variable Interest Entities of the Registrant Principal Subsidiaries Place of Incorporation Molecular Data (HK) Limited Hong Kong Shanghai MOHUA Information Technology Co., Ltd. PRC Shanghai MOKAI Biotechnology Co., Ltd. PRC Shanghai MOCHUANG Biotechnology Co., Ltd. PRC Variable Interest Entities Place of Incorporation Jiaxing MOLBASE Information Technology C

English translation of exclusive technical support and service agreement dated December 21, 2018 among Shanghai MOHUA and Jiaxing MOLBASE (incorporated herein by reference to Exhibit 10.12 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.12 17 d634677dex1012.htm EX-10.12 Exhibit 10.12 English Translation Exclusive Technical Support and Service Agreement This Exclusive Technical Support and Service Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A: Shanghai MOHUA Information Technology Co., Ltd., a wholly-forei

2018 Share Plan (incorporated herein by reference to Exhibit 10.1 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

EX-10.1 6 d634677dex101.htm EX-10.1 Exhibit 10.1 MOLECULAR DATA INC. 2018 SHARE PLAN SECTION 1. ESTABLISHMENT AND PURPOSE. The purpose of this Plan is to offer persons selected by the Company an opportunity to acquire a proprietary interest in the success of the Company, or to increase such interest, by acquiring Shares. The Plan provides both for the direct award or sale of Shares and for the gra

English translation of equity pledge agreement dated December 21, 2018 among Shanghai MOHUA, Jiaxing MOLBASE and the shareholders of Jiaxing MOLBASE (incorporated herein by reference to Exhibit 10.9 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.9 Equity Pledge Agreement This Equity Pledge Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Pledgee): Shanghai MOHUA Information Technology Co., Ltd., a wholly foreign owned enterprise legally established and validly existing under the laws of the PRC, with its regist

Form of Employment Agreement between the Registrant and its executive officers (incorporated herein by reference to Exhibit 10.4 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of , 2019 by and between Molecular Data Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the ?Company?) and (Passport/PRC ID Card No.: ) (the ?Executive?). RECITALS WHEREAS, the Company desires to employ the Executive and to assure itself of the services of the

Code of Business Conduct and Ethics of the Registrant (incorporated herein by reference to Exhibit 99.1 to the Form F-1 filed on December 6, 2019 (File No. 333-235398))

Exhibit 99.1 MOLECULAR DATA INC. CODE OF BUSINESS CONDUCT AND ETHICS I. PURPOSE This Code of Business Conduct and Ethics (the ?Code?) contains general guidelines for conducting the business of Molecular Data Inc., a Cayman Islands company, and its subsidiaries and affiliates (collectively, the ?Company?) consistent with the highest standards of business ethics, and is intended to qualify as a ?cod

MKD / Molecular Data Inc. CORRESP - -

CORRESP SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ JONATHAN B. STONE * PALOMA P. WANG ◆ (Also Admitted in England & Wales) * (Also Admitted in New York) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTRA

THE COMPANIES LAW (2018 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION MOLECULAR DATA INC. (adopted by a Special Resolution passed on October 8, 2019 and effective immediately prior to the com

EX-3.2 3 filename3.htm Exhibit 3.2 THE COMPANIES LAW (2018 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. (adopted by a Special Resolution passed on October 8, 2019 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing its Class A Ordi

As confidentially submitted to the Securities and Exchange Commission on October 30, 2019

Table of Contents As confidentially submitted to the Securities and Exchange Commission on October 30, 2019 Registration No.

MOLECULAR DATA INC. CODE OF BUSINESS CONDUCT AND ETHICS

Exhibit 99.1 MOLECULAR DATA INC. CODE OF BUSINESS CONDUCT AND ETHICS I. PURPOSE This Code of Business Conduct and Ethics (the ?Code?) contains general guidelines for conducting the business of Molecular Data Inc., a Cayman Islands company, and its subsidiaries and affiliates (collectively, the ?Company?) consistent with the highest standards of business ethics, and is intended to qualify as a ?cod

THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION MOLECULAR DATA INC. Maricorp Services Ltd. 31 The Strand PO Box 2075 Grand Cayman KY1-1105 Cayman Islands

EX-3.1 2 filename2.htm Exhibit 3.1 THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. Maricorp Services Ltd. 31 The Strand PO Box 2075 Grand Cayman KY1-1105 Cayman Islands i THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. (the “Company”) 1

MKD / Molecular Data Inc. DRSLTR - -

SKADDEN, ARPS, SLATE, MEAGHER & FLOM 世達國際律師事務所 AFFILIATE OFFICES PARTNERS CHRISTOPHER W.

INDEMNIFICATION AGREEMENT

EX-10.3 5 filename5.htm Exhibit 10.3 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of , 2019 by and between Molecular Data Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and (Passport/ID Card No. ) (the “Indemnitee”). WHEREAS, the Indemnitee has agreed to serve as a director or officer of the Compan

EMPLOYMENT AGREEMENT

Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of , 2019 by and between Molecular Data Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the ?Company?) and (Passport/PRC ID Card No.: ) (the ?Executive?). RECITALS WHEREAS, the Company desires to employ the Executive and to assure itself of the services of the

MOLECULAR DATA INC. 2019 SHARE INCENTIVE PLAN ARTICLE 1

Exhibit 10.2 MOLECULAR DATA INC. 2019 SHARE INCENTIVE PLAN ARTICLE 1 PURPOSE The purpose of the Plan is to promote the success and enhance the value of Molecular Data Inc., an exempted company formed under the laws of the Cayman Islands (the ?Company?), by linking the personal interests of the Directors, Employees, and Consultants to those of the Company?s shareholders and by providing such indivi

THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION MOLECULAR DATA INC. Maricorp Services Ltd. 31 The Strand PO Box 2075 Grand Cayman KY1-1105 Cayman Islands

Exhibit 3.1 THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. Maricorp Services Ltd. 31 The Strand PO Box 2075 Grand Cayman KY1-1105 Cayman Islands i THE COMPANIES LAW (2016 Revision)(as amended) EXEMPTED COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MOLECULAR DATA INC. (the ?Company?) 1. The NAME of the Compa

As confidentially submitted to the Securities and Exchange Commission on September 10, 2019

Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 10, 2019 Registration No.

MKD / Molecular Data Inc. DRSLTR - -

SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ JONATHAN B. STONE * PALOMA P. WANG ◆ (ALSO ADMITTED IN ENGLAND & WALES) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTRAL, HONG

Exclusive Technical Support and Service Agreement

EX-10.7 5 filename5.htm Exhibit 10.7 English Translation Exclusive Technical Support and Service Agreement This Exclusive Technical Support and Service Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A: Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterpri

Equity Pledge Agreement

EX-10.8 6 filename6.htm Exhibit 10.8 Equity Pledge Agreement This Equity Pledge Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Pledgee): Shanghai MOHUA Information Technology Co., Ltd., a wholly foreign owned enterprise legally established and validly existing under the laws of

MKD / Molecular Data Inc. DRSLTR - -

DRSLTR 1 filename1.htm SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ JONATHAN B. STONE * PALOMA P. WANG ◆ (ALSO ADMITTED IN ENGLAND & WALES) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEE

Shareholders’ Voting Rights Proxy Agreement

EX-10.10 8 filename8.htm Exhibit 10.10 English Translation Shareholders’ Voting Rights Proxy Agreement This Shareholders’ Voting Rights Proxy Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Shareholders): Dongliang Chang Identification No.: Zhengyu Wu Identification No.: Zhejiang

Equity Pledge Agreement

Exhibit 10.4 English Translation Equity Pledge Agreement This Equity Pledge Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Pledgee): Shanghai MOHUA Information Technology Co., Ltd., a wholly foreign owned enterprise legally established and validly existing under the laws of the

Exclusive Option Agreement

EX-10.5 3 filename3.htm Exhibit 10.5 English Translation Exclusive Option Agreement This Exclusive Option Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Obligee): Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterprise legally established and validly e

As confidentially submitted to the Securities and Exchange Commission on August 1, 2019

Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 1, 2019 Registration No.

Exclusive Technical Support and Service Agreement

EX-10.11 9 filename9.htm Exhibit 10.11 English Translation Exclusive Technical Support and Service Agreement This Exclusive Technical Support and Service Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A: Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterp

Exclusive Option Agreement

Exhibit 10.9 English Translation Exclusive Option Agreement This Exclusive Option Agreement (the ?Agreement?) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People?s Republic of China (the ?PRC?): Party A (Obligee): Shanghai MOHUA Information Technology Co., Ltd., a wholly-foreign-owned enterprise legally established and validly existing under the laws o

Shareholders’ Voting Rights Proxy Agreement

EX-10.6 4 filename4.htm Exhibit 10.6 English Translation Shareholders’ Voting Rights Proxy Agreement This Shareholders’ Voting Rights Proxy Agreement (the “Agreement”) is entered into by and between the following parties on December 21, 2018 in Shanghai, the People’s Republic of China (the “PRC”): Party A (Shareholders): Dongliang Chang Identification No.: Zhengyu Wu Identification No.: Party B (t

As confidentially submitted to the Securities and Exchange Commission on March 28, 2019

Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 28, 2019 Registration No.

MOLECULAR DATA INC. 2018 SHARE PLAN

Exhibit 10.1 MOLECULAR DATA INC. 2018 SHARE PLAN SECTION 1. ESTABLISHMENT AND PURPOSE. The purpose of this Plan is to offer persons selected by the Company an opportunity to acquire a proprietary interest in the success of the Company, or to increase such interest, by acquiring Shares. The Plan provides both for the direct award or sale of Shares and for the grant of Options to purchase Shares and

Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People’s Republic of China March 28, 2019

Exhibit 99.4 Molecular Data Inc. 5/F, Building 12, 1001 North Qinzhou Road Xuhui District, Shanghai 201109 People?s Republic of China March 28, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Molecular Data Inc. ? Registration Statement on Form F-1 Representation under Item 8.A.4 of Form 20-F Dear Sir/Madam, The u

MKD / Molecular Data Inc. DRSLTR - -

DRSLTR 1 filename1.htm SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * BRADLEY A. KLEIN ~ CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ JONATHAN B. STONE * ◆ (ALSO ADMITTED IN ENGLAND & WALES) ~ (ALSO ADMITTED IN ILLINOIS) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所 42/F, EDI

As confidentially submitted to the Securities and Exchange Commission on January 31, 2019

Table of Contents As confidentially submitted to the Securities and Exchange Commission on January 31, 2019 Registration No.

MKD / Molecular Data Inc. DRSLTR - -

DRSLTR PARTNERS CHRISTOPHER W. BETTS WILL H. CAI ^ GEOFFREY CHAN * ANDREW L. FOSTER * BRADLEY A. KLEIN ~ CHI T. STEVE KWOK * EDWARD H.P. LAM ◆* HAIPING LI * RORY MCALPINE ◆ CLIVE W. ROUGH ◆ JONATHAN B. STONE * ^ (ALSO ADMITTED IN CALIFORNIA) ◆ (ALSO ADMITTED IN ENGLAND & WALES) ~ (ALSO ADMITTED IN ILLINOIS) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所